These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 31932195)

  • 1. Impact of EBV infection and immune function assay for lymphoproliferative disorder in pediatric patients after liver transplantation: A single-center experience.
    Qin T; Gu XQ; Jeong SS; Song YY; Liu JC; Zheng JX; Xue F; Xia Q
    Hepatobiliary Pancreat Dis Int; 2020 Feb; 19(1):3-11. PubMed ID: 31932195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roles of Epstein-Barr virus viral load monitoring in the prediction of posttransplant lymphoproliferative disorder in pediatric liver transplantation.
    Chen HS; Ho MC; Hu RH; Wu JF; Chen HL; Ni YH; Hsu HY; Jeng YM; Chang MH
    J Formos Med Assoc; 2019 Sep; 118(9):1362-1368. PubMed ID: 30612881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epstein-Barr virus--associated posttransplantation lymphoproliferative disorder with tacrolimus metabolism deterioration in infants after living-donor liver transplantation.
    Fukushima D; Sato K; Kawagishi N; Ohuchi N; Satomi S
    Transplantation; 2015 Jan; 99(1):114-9. PubMed ID: 24846306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease.
    Smets F; Latinne D; Bazin H; Reding R; Otte JB; Buts JP; Sokal EM
    Transplantation; 2002 May; 73(10):1603-10. PubMed ID: 12042647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
    Chiereghin A; Prete A; Belotti T; Gibertoni D; Piccirilli G; Gabrielli L; Pession A; Lazzarotto T
    Transpl Infect Dis; 2016 Feb; 18(1):44-54. PubMed ID: 26574232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epstein-Barr virus-associated risk factors for post-transplant lymphoproliferative disease in pediatric liver transplant recipients.
    Quintero Bernabeu J; Juamperez J; Mercadal-Hally M; Larrarte King M; Gallego Melcon S; Gros Subias L; Sábado Álvarez C; Soler-Palacin P; Melendo Pérez S; Esperalba J; Navarro Jiménez A; Garrido Pontnou M; Camacho Soriano J; Hidalgo Llompart E; Bilbao Aguirre I; Charco Torra R
    Pediatr Transplant; 2022 Sep; 26(6):e14292. PubMed ID: 35466492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus.
    Sokal EM; Antunes H; Beguin C; Bodeus M; Wallemacq P; de Ville de Goyet J; Reding R; Janssen M; Buts JP; Otte JB
    Transplantation; 1997 Nov; 64(10):1438-42. PubMed ID: 9392308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment.
    Guthery SL; Heubi JE; Bucuvalas JC; Gross TG; Ryckman FC; Alonso MH; Balistreri WF; Hornung RW
    Transplantation; 2003 Apr; 75(7):987-93. PubMed ID: 12698085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-infection of Cytomegalovirus and Epstein-Barr Virus Diminishes the Frequency of CD56
    Lam JKP; Azzi T; Hui KF; Wong AMG; McHugh D; Caduff N; Chan KH; Münz C; Chiang AKS
    Front Immunol; 2020; 11():1231. PubMed ID: 32625211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single-center experience of post-transplant lymphoproliferative disorder (PTLD) cases after pediatric liver transplantation: Incidence, outcomes, and association with food allergy.
    Barış Z; Özçay F; Yılmaz Özbek Ö; Haberal N; Sarıalioğlu F; Haberal M
    Turk J Gastroenterol; 2018 May; 29(3):354-360. PubMed ID: 29755021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of prospective monitoring of Epstein-Barr virus DNA in blood samples of pediatric liver transplant recipients.
    Scheenstra R; Verschuuren EA; de Haan A; Slooff MJ; The TH; Bijleveld CM; Verkade HJ
    Transpl Infect Dis; 2004 Mar; 6(1):15-22. PubMed ID: 15225222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantification of a low cellular immune response to aid in identification of pediatric liver transplant recipients at high-risk for EBV infection.
    Lee TC; Goss JA; Rooney CM; Heslop HE; Barshes NR; Caldwell YM; Gee AP; Scott JD; Savoldo B
    Clin Transplant; 2006; 20(6):689-94. PubMed ID: 17100717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Seropositivity for cytomegalovirus and PCR-EBV monitoring: Protective factors for posttransplant lymphoproliferative disorder in pediatric liver transplant.
    Éboli LPCB; Tannuri ACA; Tannuri U
    Pediatr Transplant; 2022 Jun; 26(4):e14226. PubMed ID: 35037358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viral load of EBV DNAemia is a predictor of EBV-related post-transplant lymphoproliferative disorders in pediatric renal transplant recipients.
    Colombini E; Guzzo I; Morolli F; Longo G; Russo C; Lombardi A; Merli P; Barzon L; Murer L; Piga S; Ciofi Degli Atti ML; Locatelli F; Dello Strologo L
    Pediatr Nephrol; 2017 Aug; 32(8):1433-1442. PubMed ID: 28280938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
    J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epstein-Barr virus related post-transplant lymphoproliferative disorder prevention strategies in allogeneic hematopoietic stem cell transplantation.
    Lindsay J; Yong MK; Greenwood M; Kong DCM; Chen SCA; Rawlinson W; Slavin M
    Rev Med Virol; 2020 Jul; 30(4):e2108. PubMed ID: 32301566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreasing incidence of symptomatic Epstein-Barr virus disease and posttransplant lymphoproliferative disorder in pediatric liver transplant recipients: report of the studies of pediatric liver transplantation experience.
    Narkewicz MR; Green M; Dunn S; Millis M; McDiarmid S; Mazariegos G; Anand R; Yin W;
    Liver Transpl; 2013 Jul; 19(7):730-40. PubMed ID: 23696264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Posttransplant lymphoproliferative disorders and gastrointestinal manifestations of Epstein-Barr virus infection in children following liver transplantation.
    Cao S; Cox K; Esquivel CO; Berquist W; Concepcion W; Ojogho O; Monge H; Krams S; Martinez O; So S
    Transplantation; 1998 Oct; 66(7):851-6. PubMed ID: 9798693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Early diagnosis and comprehensive treatments of post-transplantation lymphoproliferative disorder after pediatric liver transplantation].
    Deng Z; Jiang L; Zhou T; Shen C; Chen Q; Xia Q
    Zhonghua Er Ke Za Zhi; 2014 Aug; 52(8):579-82. PubMed ID: 25224233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients.
    Lee TC; Savoldo B; Rooney CM; Heslop HE; Gee AP; Caldwell Y; Barshes NR; Scott JD; Bristow LJ; O'Mahony CA; Goss JA
    Am J Transplant; 2005 Sep; 5(9):2222-8. PubMed ID: 16095501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.